|Articles|March 18, 2019

MALDI-8020: Small size. Massive impact

The MALDI-8020 is the latest in a long line of MALDI-TOF products from Shimadzu. This benchtop, linear MALDI-TOF mass spectrometer delivers outstanding performance in a compact footprint, making it an ideal choice for today’s increasingly demanding laboratories.

The MALDI-8020 is the latest in a long line of MALDI-TOF products from Shimadzu. This benchtop, linear MALDI-TOF mass spectrometer delivers outstanding performance in a compact footprint, making it an ideal choice for today’s increasingly demanding laboratories.

 

Key features:

  • Linear mode (positive ion) MALDI-TOF

  • 200 Hz solid‒state laser, 355 nm

  • Load-lock chamber for fast sample introduction

  • UV laser‒based source cleaning (patented)

  • Small size due to benchtop design with a compact footprint

  • Quiet operation (<55 dB)

 

Linear mode instruments have traditionally been the instruments of choice in MALDI-TOF-based quality control (QC) and profiling workflows, and the MALDI-8020 is no exception. Peptides, proteins, polymers or oligonucleotides ‒ the instrument is capable of delivering the performance required for QC applications. Research laboratories will also benefit from the MS capabilities of the instrument through the rapid mass-measurement of samples.

 

Contact Details:

Company Name: Shimadzu Europa GmbH
Website: www.shimadzu.eu
Email: shimadzu@shimadzu.eu

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.